Hyderabad-based PSU Indian Immunologicals Limited has obtained a mortgage license from drug regulator CDSCO for supplying to Bharat Biotech Covaxin drug substance produced at its repurposed facility, the Department of Biotechnology (DBT) mentioned on Friday.
The DBT and the Biotechnology Industry Research Council (BIRAC), underneath Mission Covid Suraksha, launched a undertaking to reinforce the manufacturing capability of Covaxin, the anti-coronavirus vaccine developed by Bharat Biotech.
“Indian Immunologicals Limited, Hyderabad is the first site under this project to receive from CDSCO (Central Drugs Standard Control Organisation) a loan license for supplying Covaxin drug substance produced at its repurposed facility to Bharat Biotech,” the DBT mentioned.
IIL is likely one of the three public sector undertakings to have been tasked with manufacturing Covaxin doses. It provided the primary lot of economic Covaxin drug substance to Bharat Biotech on Friday.
Initially, the IIL will produce 2-3 million doses per 30 days, adopted by one other 4-5 million doses from its new facility at Karkapatla over the subsequent few weeks.
Secretary, DBT and BIRAC chairperson Renu Swarup mentioned the federal government has labored relentlessly to supply all attainable help for ramping up Covaxin manufacturing within the nation and velocity up the Covaxin inoculation drive.
“The loan license agreement by CDSCO for Indian Immunologicals to produce Covaxin drug substance is a major milestone achieved in a very short span of time.”
“The DBT-BIRAC support under Mission Covid Suraksha aims to meet the COVID-19 vaccine requirement of our country. I congratulate the team for the efforts put in for this achievement,” she mentioned.
(Except for the headline, this story has not been edited by India07 employees and is revealed from a syndicated feed.)
(THIS STORY HAS NOT BEEN EDITED BY INDIA07 TEAM AND IS AUTO-GENERATED FROM A SYNDICATED FEED.)